You just read:

Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

News provided by

Jazz Pharmaceuticals plc

Dec 21, 2018, 07:00 ET